
Opinion|Videos|July 1, 2024
Key Takeaways on the Evolving NMIBC Treatment Landscape
The panel concludes by offering key takeaways on the evolving treatment landscape for BCG-unresponsive non–muscle invasive bladder cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
3
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
4
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
5














